{"slideshow_credits": null, "snippet": "The closely watched experimental drug, dexpramipexole, failed to work in a late-stage clinical trial, disappointing medical experts.", "abstract": "Biogen ends development of closely watched experimental drug dexpramipexole, which medical experts hoped would be useful tool to treat amyotrophic lateral sclerlosis, known as ALS or Lou Gehrig's disease, after it fails to work in a late-stage clinical trial.", "section_name": "Business Day", "print_page": "2", "document_type": "article", "byline": {"person": [{"firstname": "Andrew", "role": "reported", "lastname": "POLLACK", "rank": 1, "organization": ""}], "original": "By ANDREW POLLACK", "contributor": ""}, "web_url": "http://www.nytimes.com/2013/01/04/business/company-gives-up-on-drug-for-lou-gehrigs-disease.html", "lead_paragraph": "The closely watched experimental drug, dexpramipexole, failed to work in a late-stage clinical trial, disappointing medical experts.", "headline": {"main": "Biogen Idec Gives Up on Drug for Lou Gehrig\u2019s Disease", "print_headline": "Biogen Idec Gives Up on Drug for Lou Gehrig\u2019s Disease"}, "_id": "50e599f400315214fbb8236e", "word_count": "602", "multimedia": [], "pub_date": "2013-01-04T00:00:00Z", "source": "The New York Times", "news_desk": "Business", "keywords": [{"value": "Drugs (Pharmaceuticals)", "name": "subject", "is_major": "Y", "rank": "1"}, {"value": "Amyotrophic Lateral Sclerosis", "name": "subject", "is_major": "Y", "rank": "2"}, {"value": "Clinical Trials", "name": "subject", "is_major": "N", "rank": "3"}, {"value": "Biogen Idec Inc", "name": "organizations", "is_major": "Y", "rank": "4"}], "blog": [], "subsection_name": null, "type_of_material": "News"}